Wall Street brokerages expect Neon Therapeutics Inc (NASDAQ:NTGN) to announce earnings per share (EPS) of ($0.67) for the current quarter, Zacks reports. Zero analysts have issued estimates for Neon Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.70) and the highest estimate coming in at ($0.64). The firm is scheduled to report its next earnings report on Monday, February 11th.

According to Zacks, analysts expect that Neon Therapeutics will report full year earnings of ($5.17) per share for the current year, with EPS estimates ranging from ($5.50) to ($4.84). For the next financial year, analysts forecast that the company will report earnings of ($3.06) per share, with EPS estimates ranging from ($3.44) to ($2.70). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Neon Therapeutics.

Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings results on Monday, November 12th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.12.

NTGN has been the subject of several research analyst reports. LADENBURG THALM/SH SH initiated coverage on Neon Therapeutics in a research report on Monday, October 1st. They set a “buy” rating and a $20.00 price objective for the company. Zacks Investment Research raised Neon Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research report on Friday, November 16th. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $18.08.

Institutional investors and hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC bought a new position in Neon Therapeutics during the second quarter valued at about $1,467,000. Bain Capital Public Equity Management LLC bought a new position in Neon Therapeutics during the second quarter valued at about $147,000. United Services Automobile Association bought a new position in Neon Therapeutics during the second quarter valued at about $607,000. Point72 Hong Kong Ltd bought a new position in Neon Therapeutics during the second quarter valued at about $105,000. Finally, Maso Capital Partners Ltd bought a new position in Neon Therapeutics during the second quarter valued at about $441,000. Hedge funds and other institutional investors own 71.09% of the company’s stock.

Shares of NASDAQ:NTGN traded down $0.61 on Monday, reaching $5.54. The company had a trading volume of 190 shares, compared to its average volume of 99,959. Neon Therapeutics has a twelve month low of $5.62 and a twelve month high of $16.23.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Read More: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.